Hippocampus-specific deletion of tissue plasminogen activator "tPA" in adult mice impairs depression- and anxiety-like behaviors

European Neuropsychopharmacology

Volumn 22, Issue 9, 2012, Pages 672-682

  Bahi, Amine ^a   Dreyer, Jean Luc ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b University of Fribourg   (Switzerland)

Author keywords

Anxiety; BDNF; Depression; Elevated plus maze; Forced swim test; Lentivirus; Marble burying test; ShRNA; Tail suspension; TPA

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; GENE DELETION; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS;

ANIMALS; ANXIETY; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HIPPOCAMPUS; LENTIVIRUS; MALE; MICE; MICE, INBRED C57BL; MICROINJECTIONS; RNA, SMALL INTERFERING; STRESS, PSYCHOLOGICAL; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84864992594     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.01.008     Document Type: Article

References (91)

1. Abe M., Nakai H., Tabata R., Saito K., Egawa M. Effect of 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3-benzodioxole HCl (MKC-242), a novel 5-HT1A-receptor agonist, on aggressive behavior and marble burying behavior in mice. Jpn. J. Pharmacol. 1998, 76:297-304.
2. Bahi A., Dreyer J.L. Overexpression of plasminogen activators in the nucleus accumbens enhances cocaine-, amphetamine- and morphine-induced reward and behavioral sensitization. Genes Brain Behav. 2008, 7:244-256.
3. Bahi A., Dreyer J.L. Involvement of tissue plasminogen activator "tPA" in ethanol-induced locomotor sensitization and conditioned-place preference. Behav. Brain Res. 2011, 226:250-258.
4. Bahi A., Boyer F., Gumy C., Kafri T., Dreyer J.L. In vivo gene delivery of urokinase-type plasminogen activator with regulatable lentivirus induces behavioural changes in chronic cocaine administration. Eur. J. Neurosci. 2004, 20:3473-3488.
5. Bahi A., Boyer F., Kafri T., Dreyer J.L. CD81-induced behavioural changes during chronic cocaine administration: in vivo gene delivery with regulatable lentivirus. Eur. J. Neurosci. 2004, 19:1621-1633.
6. Bahi A., Boyer F., Bussard G., Dreyer J.L. Silencing dopamine D3-receptors in the nucleus accumbens shell in vivo induces changes in cocaine-induced hyperlocomotion. Eur. J. Neurosci. 2005, 21:3415-3426.
7. Bahi A., Boyer F., Kolira M., Dreyer J.L. In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behaviour. J. Neurochem. 2005, 92:1243-1255.
8. Bahi A., Boyer F., Kafri T., Dreyer J.L. Silencing urokinase in the ventral tegmental area in vivo induces changes in cocaine-induced hyperlocomotion. J. Neurochem. 2006, 98:1619-1631.
9. Bahi A., Boyer F., Chandrasekar V., Dreyer J.L. Role of accumbens BDNF and TrkB in cocaine-induced psychomotor sensitization, conditioned-place preference, and reinstatement in rats. Psychopharmacology (Berl) 2008, 199:169-182.
10. Bahi A., Kusnecov A., Dreyer J.L. The role of tissue-type plasminogen activator system in amphetamine-induced conditional place preference extinction and reinstatement. Neuropsychopharmacology 2008, 33:2726-2734.
11. Bahi A., Kusnecov A.W., Dreyer J.L. Effects of urokinase-type plasminogen activator in the acquisition, expression and reinstatement of cocaine-induced conditioned-place preference. Behav. Brain Res. 2008, 191:17-25.
12. Bahi A., Mineur Y.S., Picciotto M.R. Blockade of protein phosphatase 2B activity in the amygdala increases anxiety- and depression-like behaviors in mice. Biol. Psychiatry 2009, 66:1139-1146.
13. Barnes P., Thomas K.L. Proteolysis of proBDNF is a key regulator in the formation of memory. PLoS One 2008, 3:e3248.
14. Bennur S., Shankaranarayana Rao B.S., Pawlak R., Strickland S., McEwen B.S., Chattarji S. Stress-induced spine loss in the medial amygdala is mediated by tissue-plasminogen activator. Neuroscience 2007, 144:8-16.
15. Britton K.T., Page M., Baldwin H., Koob G.F. Anxiolytic activity of steroid anesthetic alphaxalone. J. Pharmacol. Exp. Ther. 1991, 258:124-129.
16. Corbett R., Fielding S., Cornfeldt M., Dunn R.W. GABAmimetic agents display anxiolytic-like effects in the social interaction and elevated plus maze procedures. Psychopharmacology (Berl) 1991, 104:312-316.
17. Diamond S.L., Sharefkin J.B., Dieffenbach C., Frasier-Scott K., McIntire L.V., Eskin S.G. Tissue plasminogen activator messenger RNA levels increase in cultured human endothelial cells exposed to laminar shear stress. J. Cell. Physiol. 1990, 143:364-371.
18. D'Sa C., Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord. 2002, 4:183-194.
19. Dunn R.W., Corbett R., Fielding S. Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur. J. Pharmacol. 1989, 169:1-10.
20. Enoch M.A., White K.V., Waheed J., Goldman D. Neurophysiological and genetic distinctions between pure and comorbid anxiety disorders. Depress Anxiety 2008, 25:383-392.
21. Fernandez-Guasti A., Reyes R., Martinez-Mota L., Lopez-Munoz F.J. Influence of inflammatory nociception on the anxiolytic-like effect of diazepam and buspirone in rats. Psychopharmacology (Berl) 2005, 180:399-407.
22. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 1996, New York.
23. Gadotti V.M., Bonfield S.P., Zamponi G.W. Depressive-like behaviour of mice lacking cellular prion protein. Behav. Brain Res. 2012, 227:319-323.
24. Golda V., Petr R. Animal model of anxiety: effect of acute diazepam treatment in the older adult genetically hypertensive rats of Koletsky type and in the older adult rats of Wistar strain. Sb. Ved. Pr. Lek. Fak. Karlovy Univerzity Hradci Kralove 1989, 32:407-423.
25. Gruart A., Sciarretta C., Valenzuela-Harrington M., Delgado-Garcia J.M., Minichiello L. Mutation at the TrkB PLC {gamma}-docking site affects hippocampal LTP and associative learning in conscious mice. Learn. Mem. 2007, 14:54-62.
26. Guilloux J.P., David D.J., Xia L., Nguyen H.T., Rainer Q., Guiard B.P., Reperant C., Deltheil T., Toth M., Hen R., Gardier A.M. Characterization of 5-HT (1A/1B)-/- mice: an animal model sensitive to anxiolytic treatments. Neuropharmacology 2011, 61:478-488.
27. Hevey D., McGee H.M., Fitzgerald D., Horgan J.H. Acute psychological stress decreases plasma tissue plasminogen activator (tPA) and tissue plasminogen activator/plasminogen activator inhibitor-1 (tPA/PAI-1) complexes in cardiac patients. Eur. J. Appl. Physiol. 2000, 83:344-348.
28. Hou S.J., Yen F.C., Tsai S.J. Is dysfunction of the tissue plasminogen activator (tPA)-plasmin pathway a link between major depression and cardiovascular disease?. Med. Hypotheses 2009, 72:166-168.
29. Iba T., Sumpio B.E. Tissue plasminogen activator expression in endothelial cells exposed to cyclic strain in vitro. Cell Transplant. 1992, 1:43-50.
30. Karakas A., Coskun H., Kaya A., Kucuk A., Gunduz B. The effects of the intraamygdalar melatonin injections on the anxiety like behavior and the spatial memory performance in male Wistar rats. Behav. Brain Res. 2011, 222:141-150.
31. Kauer-Sant'Anna M., Tramontina J., Andreazza A.C., Cereser K., da Costa S., Santin A., Yatham L.N., Kapczinski F. Traumatic life events in bipolar disorder: impact on BDNF levels and psychopathology. Bipolar Disord. 2007, 9(Suppl. 1):128-135.
32. Kim Y.K., Lee H.P., Won S.D., Park E.Y., Lee H.Y., Lee B.H., Lee S.W., Yoon D., Han C., Kim D.J., Choi S.H. Low plasma BDNF is associated with suicidal behavior in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:78-85.
33. Kobayashi K., Shimizu E., Hashimoto K., Mitsumori M., Koike K., Okamura N., Koizumi H., Ohgake S., Matsuzawa D., Zhang L., Nakazato M., Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:658-663.
34. Lang U.E., Hellweg R., Kalus P., Bajbouj M., Lenzen K.P., Sander T., Kunz D., Gallinat J. Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berl) 2005, 180:95-99.
35. Lee B.H., Kim H., Park S.H., Kim Y.K. Decreased plasma BDNF level in depressive patients. J. Affect. Disord. 2007, 101:239-244.
36. Levin E.G., Santell L., Saljooque F. Hyperosmotic stress stimulates tissue plasminogen activator expression by a PKC-independent pathway. Am. J. Physiol. 1993, 265:C387-C396.
37. Li Y., Luikart B.W., Birnbaum S., Chen J., Kwon C.H., Kernie S.G., Bassel-Duby R., Parada L.F. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 2008, 59:399-412.
38. Liang Y., Shaw A.M., Boules M., Briody S., Robinson J., Oliveros A., Blazar E., Williams K., Zhang Y., Carlier P.R., Richelson E. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). J. Pharmacol. Exp. Ther. 2008, 327:573-583.
39. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987, 92:180-185.
40. Liu J., Perez S.M., Zhang W., Lodge D.J., Lu X.Y. Selective deletion of the leptin receptor in dopamine neurons produces anxiogenic-like behavior and increases dopaminergic activity in amygdala. Mol. Psychiatry 2011, 16:1024-1038.
41. Lochner J.E., Honigman L.S., Grant W.F., Gessford S.K., Hansen A.B., Silverman M.A., Scalettar B.A. Activity-dependent release of tissue plasminogen activator from the dendritic spines of hippocampal neurons revealed by live-cell imaging. J. Neurobiol. 2006, 66:564-577.
42. Lohman R.J., O'Brien T.J., Cocks T.M. Protease-activated receptor-2 regulates trypsin expression in the brain and protects against seizures and epileptogenesis. Neurobiol. Dis. 2008, 30:84-93.
43. Lyons W.E., Mamounas L.A., Ricaurte G.A., Coppola V., Reid S.W., Bora S.H., Wihler C., Koliatsos V.E., Tessarollo L. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:15239-15244.
44. Matrisciano F., Bonaccorso S., Ricciardi A., Scaccianoce S., Panaccione I., Wang L., Ruberto A., Tatarelli R., Nicoletti F., Girardi P., Shelton R.C. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J. Psychiatr. Res. 2009, 43:247-254.
45. Matys T., Pawlak R., Matys E., Pavlides C., McEwen B.S., Strickland S. Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:16345-16350.
46. Melchor J.P., Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb. Haemost. 2005, 93:655-660.
47. Minelli A., Zanardini R., Bonvicini C., Sartori R., Pedrini L., Gennarelli M., Bocchio-Chiavetto L. BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261:323-329.
48. Mitoma M., Yoshimura R., Sugita A., Umene W., Hori H., Nakano H., Ueda N., Nakamura J. Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?. 'acol. Biol. Psychiatry 2008, 32:679-685.
49. Montag C., Basten U., Stelzel C., Fiebach C.J., Reuter M. The BDNF Val66Met polymorphism and anxiety: support for animal knock-in studies from a genetic association study in humans. Psychiatry Res. 2010, 179:86-90.
50. Moser P.C. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology (Berl) 1989, 99:48-53.
51. Musumeci G., Sciarretta C., Rodriguez-Moreno A., Al Banchaabouchi M., Negrete-Diaz V., Costanzi M., Berno V., Egorov A.V., von Bohlen Und Halbach O., Cestari V., Delgado-Garcia J.M., Minichiello L. TrkB modulates fear learning and amygdalar synaptic plasticity by specific docking sites. J. Neurosci. 2009, 29:10131-10143.
52. Nagai T., Nabeshima T., Yamada K. Basic and translational research on proteinase-activated receptors: regulation of nicotine reward by the tissue plasminogen activator (tPA)-plasmin system via proteinase-activated receptor 1. J. Pharmacol. Sci. 2008, 108:408-414.
53. Njung'e K., Handley S.L. Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br. J. Pharmacol. 1991, 104:105-112.
54. Noble E.E., Billington C.J., Kotz C.M., Wang C. The lighter side of BDNF. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 300:R1053-R1069.
55. Noel M., Norris E.H., Strickland S. Tissue plasminogen activator is required for the development of fetal alcohol syndrome in mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5069-5074.
56. Nollert M.U., Diamond S.L., McIntire L.V. Hydrodynamic shear stress and mass transport modulation of endothelial cell metabolism. Biotechnol. Bioeng. 1991, 38:588-602.
57. Nomikos G.G., Spyraki C. Influence of oestrogen on spontaneous and diazepam-induced exploration of rats in an elevated plus maze. Neuropharmacology 1988, 27:691-696.
58. Numakawa T., Suzuki S., Kumamaru E., Adachi N., Richards M., Kunugi H. BDNF function and intracellular signaling in neurons. Histol. Histopathol. 2010, 25:237-258.
59. Olivier J.D., Van Der Hart M.G., Van Swelm R.P., Dederen P.J., Homberg J.R., Cremers T., Deen P.M., Cuppen E., Cools A.R., Ellenbroek B.A. A study in male and female 5-HT transporter knockout rats: an animal model for anxiety and depression disorders. Neuroscience 2008, 152:573-584.
60. Ortiz O., Delgado-Garcia J.M., Espadas I., Bahi A., Trullas R., Dreyer J.L., Gruart A., Moratalla R. Associative learning and CA3-CA1 synaptic plasticity are impaired in D1R null, Drd1a-/- mice and in hippocampal siRNA silenced Drd1a mice. J. Neurosci. 2010, 30:12288-12300.
61. Pang P.T., Teng H.K., Zaitsev E., Woo N.T., Sakata K., Zhen S., Teng K.K., Yung W.H., Hempstead B.L., Lu B. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004, 306:487-491.
62. Parolini S., Flagiello D., Cinquetti A., Gozzi R., Cristini S., Cappiello J., Nicolai P., Rusnati M., Presta M., Tosatti M.M. Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br. J. Cancer 1996, 74:1168-1174.
63. Pawlak R., Magarinos A.M., Melchor J., McEwen B., Strickland S. Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat. Neurosci. 2003, 6:168-174.
64. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
65. Pietraszek M.H., Takahashi S., Takada Y., Ohara K., Inatomi H., Kondo N., Ohara K., Takada A. Diurnal patterns of serotonin, 5-hydroxyindoleacetic acid, tryptophan and fibrinolytic activity in blood of depressive patients and healthy volunteers. Thromb. Res. 1991, 64:243-252.
66. Popova N.K., Morozova M.V., Naumenko V.S. Ameliorative effect of BDNF on prenatal ethanol and stress exposure-induced behavioral disorders. Neurosci. Lett. 2011, 505:82-86.
67. Pothakos K., Robinson J.K., Gravanis I., Marsteller D.A., Dewey S.L., Tsirka S.E. Decreased serotonin levels associated with behavioral disinhibition in tissue plasminogen activator deficient (tPA-/-) mice. Brain Res. 2010, 1326:135-142.
68. Qian Z., Gilbert M.E., Colicos M.A., Kandel E.R., Kuhl D. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993, 361:453-457.
69. Rex A., Marsden C.A., Fink H. Effect of diazepam on cortical 5-HT release and behaviour in the guinea-pig on exposure to the elevated plus maze. Psychopharmacology (Berl) 1993, 110:490-496.
70. Rios M., Fan G., Fekete C., Kelly J., Bates B., Kuehn R., Lechan R.M., Jaenisch R. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol. Endocrinol. 2001, 15:1748-1757.
71. Sales A.J., Biojone C., Terceti M.S., Guimaraes F.S., Gomes M.V., Joca S.R. Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA methylation inhibitors. Br. J. Pharmacol. 2011, 164:1711-1721.
72. Sartori C.R., Vieira A.S., Ferrari E.M., Langone F., Tongiorgi E., Parada C.A. The antidepressive effect of the physical exercise correlates with increased levels of mature BDNF, and proBDNF proteolytic cleavage-related genes, p11 and tPA. Neuroscience 2011, 180:9-18.
73. Schmidt H.D., Duman R.S. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010, 35:2378-2391.
74. Seeds N.W., Basham M.E., Haffke S.P. Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:14118-14123.
75. Shi Y., You J., Yuan Y., Zhang X., Li H., Hou G. Plasma BDNF and tPA are associated with late-onset geriatric depression. Psychiatry Clin Neurosci 2010, 64:249-254.
76. Shieh C.H., Hong C.J., Huang Y.H., Tsai S.J. Potential antidepressant properties of cysteamine on hippocampal BDNF levels and behavioral despair in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1590-1594.
77. Sjogren L.S., Gan L., Doroudi R., Jern C., Jungersten L., Jern S. Fluid shear stress increases the intra-cellular storage pool of tissue-type plasminogen activator in intact human conduit vessels. Thromb. Haemost. 2000, 84:291-298.
78. Strohle A., Stoy M., Graetz B., Scheel M., Wittmann A., Gallinat J., Lang U.E., Dimeo F., Hellweg R. Acute exercise ameliorates reduced brain-derived neurotrophic factor in patients with panic disorder. Psychoneuroendocrinology 2010, 35:364-368.
79. Teesalu T., Kulla A., Asser T., Koskiniemi M., Vaheri A. Tissue plasminogen activator as a key effector in neurobiology and neuropathology. Biochem. Soc. Trans. 2002, 30:183-189.
80. Tsai S.J. The possible role of tissue-type plasminogen activator and the plasminogen system in the pathogenesis of major depression. Med. Hypotheses 2006, 66:319-322.
81. Tsai S.J. The P11, tPA/plasminogen system and brain-derived neurotrophic factor: Implications for the pathogenesis of major depression and the therapeutic mechanism of antidepressants. Med. Hypotheses 2007, 68:180-183.
82. Tsai S.J. Statins may enhance the proteolytic cleavage of proBDNF: implications for the treatment of depression. Med. Hypotheses 2007, 68:1296-1299.
83. Ueba H., Kawakami M., Yaginuma T. Shear stress as an inhibitor of vascular smooth muscle cell proliferation. Role of transforming growth factor-beta 1 and tissue-type plasminogen activator. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1512-1516.
84. Umathe S.N., Manna S.S., Jain N.S. Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice. Behav. Brain Res. 2011, 223:125-134.
85. Uz T., Dimitrijevic N., Tueting P., Manev H. 5-Lipoxygenase (5LOX)-deficient mice express reduced anxiety-like behavior. Restor. Neurol. Neurosci. 2002, 20:15-20.
86. Wu Y.P., Siao C.J., Lu W., Sung T.C., Frohman M.A., Milev P., Bugge T.H., Degen J.L., Levine J.M., Margolis R.U., Tsirka S.E. The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate. J. Cell Biol. 2000, 148:1295-1304.
87. Yang Z., Tao J., Wang J.M., Tu C., Xu M.G., Wang Y., Pan S.R. Shear stress contributes to t-PA mRNA expression in human endothelial progenitor cells and nonthrombogenic potential of small diameter artificial vessels. Biochem. Biophys. Res. Commun. 2006, 342:577-584.
88. Yang L., Zhang Z., Sun D., Xu Z., Yuan Y., Zhang X., Li L. Low serum BDNF may indicate the development of PSD in patients with acute ischemic stroke. Int. J. Geriatr. Psychiatry 2011, 26:495-502.
89. Zangrossi H., Leite J.R., Graeff F.G. Anxiolytic effect of carbamazepine in the elevated plus-maze: possible role of adenosine. Psychopharmacology (Berl) 1992, 106:85-89.
90. Zhou Y., Maiya R., Norris E.H., Kreek M.J., Strickland S. Involvement of tissue plasminogen activator in stress responsivity during acute cocaine withdrawal in mice. Stress 2010, 13:481-490.
91. Zorio E., Gilabert-Estelles J., Espana F., Ramon L.A., Cosin R., Estelles A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr. Med. Chem. 2008, 15:923-929.